约翰C分庭

抽象性 :胆固醇、低密度脂质胆固醇、高密度脂质胆固醇和三甘酸基因组筛选出泛欧祖先 超过十万个体中 等离子体脂质相关常见变异95大关联loci(P < 5x10-8),59显示全基因组与脂质首次有显著关联新报告关联包括单核多态学近已知脂质调节器(例如CYP7A1、NPC1L1和SCARB1),并包括数十种先前未与脂质代谢95Loci不仅有助于脂质的正常变异,还有助于极端脂型并影响三大非欧族(东亚人、南亚人和非裔美国人)的脂质特征与等离子体脂素相关联 并发CAD最后,我们验证三大新基因GALNT2、PPP1R3B和TTC39B实验鼠标模型综合起来,我们的发现为深入生物理解脂质新陈代谢并发现预防CAD新治疗机会打下基础

抽象性 :肥胖易染多病深入理解肥胖基因基础,在此,我们进行全基因组关联学和Metabochip人体质指数元分析,这是用于定义肥胖和评估共达339224人的常用度量法分析识别97BMI关联loci路径分析强力支持中枢神经系统在肥胖易感性并隐含新基因和路径方面的作用,包括与语法函数相关联的基因和路径、浮质信号传导、隔音分解/动作、能量代谢、脂生物和二分位生成

抽象性 :低密度脂质胆固醇(LDL)胆固醇、高密度脂质胆固醇(HDL)胆固醇、三甘酸识别并精炼已知传教物影响这些脂质,我们用全基因组定制基因组数组检验188 577名个人P < 5x10(-8)中与脂度相关联的157oci,包括62oci先前与人体脂度无关使用欧洲、东亚、南亚和非洲祖先密集基因学,我们在12oci缩小关联信号与血脂水平相关联地常与心血管和代谢特征相关联,包括冠动脉病、2型糖尿病、血压、腰部比和体积指数betway亚洲并深入了解生物机制调节血脂以指导未来的遗传、生物和治疗研究。

抽象性 :缩略语:ARVD超富阻塞性心电图、LVT左波流道、MR二分调试、MS二分调试、MS二分调试松化、MVA单向流转区、DP压梯度、RVT右心电图、SVT切分流

抽象性 :CONTEXT:建议总同性富集与缺热心脏病和中风风险相关Objective:评估同性富集与血管疾病风险之间的关系数据搜索网搜索1966年1月至1999年1月发布的文章相关研究通过系统搜索文献识别所有报告观察研究IHD或中风风险与同系物富集间关联通过手搜原创文章或评论文章的参考文献以及与相关调查人员个人通信识别了额外研究研究选择:研究包括到1999年1月时是否有关于全同性聚积度、性别和年龄发生事件的数据研究如果只测量自由同系物或测试后同系物的血富集度或相关临床数据缺或不完整则排除研究数据示例:30项预测或回溯研究中的数据共涉及5 073 IHD事件和1113中程事件,被纳入单个参与者数据元分析中,并允许研究间差异、已知心血管风险因素混淆和回归稀释偏差IHD和中风关联并发性同源物富集通过使用条件性逻辑回归获取DATASYSIS:回溯性研究中观察到较强关联性,该研究用疾病发病后采集的血液测量,比未来研究中在采集血液时没有心血管病历史的人中发现强联性强调整已知心血管风险因素和回归稀释偏差后,同系物水平(约3微摩尔/升[0.41 mg/L])低25%常数(为回归稀释偏差修正)与11%相关联(OR,0.89!95%置信区间,0.83-0.96低IHD风险和19%(OR,0.81!95%CI 0.69-0.95低中风风险结论:对观察研究的元分析显示,高同性器充其量只是IHD和中风风险的健康群中适量独立预测器基因变异影响同源物浓度研究将有助于确定同源物是否因果与血管疾病相关,如大规模随机测试IHD效应和维他命补丁降低同源物浓度

抽象性 :ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AHEAD : Action for HEAlth in Diabetes ALLHAT : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack ALTITUDE : ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints ANTIPAF : ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation APOLLO : A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People ARB : angiotensin receptor blocker ARIC : Atherosclerosis Risk In Communities ARR : aldosterone renin ratio ASCOT : Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-LLA : Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm ASTRAL : Angioplasty and STenting for Renal Artery Lesions A-V : atrioventricular BB : beta-blocker BMI : body mass index BP : blood pressure BSA : body surface area CA : calcium antagonist CABG : coronary artery bypass graft CAPPP : CAPtopril Prevention Project CAPRAF : CAndesartan in the Prevention of Relapsing Atrial Fibrillation CHD : coronary heart disease CHHIPS : Controlling Hypertension and Hypertension Immediately Post-Stroke CKD : chronic kidney disease CKD-EPI : Chronic Kidney Disease—EPIdemiology collaboration CONVINCE : Controlled ONset Verapamil INvestigation of CV Endpoints CT : computed tomography CV : cardiovascular CVD : cardiovascular disease D : diuretic DASH : Dietary Approaches to Stop Hypertension DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Study DIRECT : DIabetic REtinopathy Candesartan Trials DM : diabetes mellitus DPP-4 : dipeptidyl peptidase 4 EAS : European Atherosclerosis Society EASD : European Association for the Study of Diabetes ECG : electrocardiogram EF : ejection fraction eGFR : estimated glomerular filtration rate ELSA : European Lacidipine Study on Atherosclerosis ESC : European Society of Cardiology ESH : European Society of Hypertension ESRD : end-stage renal disease EXPLOR : Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination FDA : U.S.Food and Drug Administration FEVER : Felodipine EVent Reduction study GISSI-AF : Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation HbA1c : glycated haemoglobin HBPM : home blood pressure monitoring HOPE : Heart Outcomes Prevention Evaluation HOT : Hypertension Optimal Treatment HRT : hormone replacement therapy HT : hypertension HYVET : HYpertension in the Very Elderly Trial IMT : intima-media thickness I-PRESERVE : Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART : Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries INVEST : INternational VErapamil SR/T Trandolapril ISH : Isolated systolic hypertension JNC : Joint National Committee JUPITER : Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin LAVi : left atrial volume index LIFE : Losartan Intervention For Endpoint Reduction in Hypertensives LV : left ventricle/left ventricular LVH : left ventricular hypertrophy LVM : left ventricular mass MDRD : Modification of Diet in Renal Disease MRFIT : Multiple Risk Factor Intervention Trial MRI : magnetic resonance imaging NORDIL : The Nordic Diltiazem Intervention study OC : oral contraceptive OD : organ damage ONTARGET : ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial PAD : peripheral artery disease PATHS : Prevention And Treatment of Hypertension Study PCI : percutaneous coronary intervention PPAR : peroxisome proliferator-activated receptor PREVEND : Prevention of REnal and Vascular ENdstage Disease PROFESS : Prevention Regimen for Effectively Avoiding Secondary Strokes PROGRESS : Perindopril Protection Against Recurrent Stroke Study PWV : pulse wave velocity QALY : Quality adjusted life years RAA : renin-angiotensin-aldosterone RAS : renin-angiotensin system RCT : randomized controlled trials RF : risk factor ROADMAP : Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention SBP : systolic blood pressure SCAST : Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke SCOPE : Study on COgnition and Prognosis in the Elderly SCORE : Systematic COronary Risk Evaluation SHEP : Systolic Hypertension in the Elderly Program STOP : Swedish Trials in Old Patients with Hypertension STOP-2 : The second Swedish Trial in Old Patients with Hypertension SYSTCHINA : SYSTolic Hypertension in the Elderly: Chinese trial SYSTEUR : SYSTolic Hypertension in Europe TIA : transient ischaemic attack TOHP : Trials Of Hypertension Prevention TRANSCEND : Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans' Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use Evaluation WHO : World Health Organization ### 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …

抽象性 :千基因组项目综合描述人类常见基因变异,对多群化的多元化个人群应用全基因序列重构26组2 504人的基因组 使用低覆盖全基因排序 深片测序 稠密微数组演算八千八百多万变异物(8 470万单核多态化物(SNPssssssssssssssssssssssss)360万短插入/删除(indelssssssssssssss)和60万结构变异物sssse资源中包含>99%sNP变异,频率为>1%我们描述基因变异分布全局样本 并讨论对常见疾病研究的影响

抽象性 :过去十年快速技术开发以及这些开发带来的回声心机实践变化导致需要更新建议以补充此前出版的心室量化指南,这是美国心机学会和欧洲心机成像协会联合编译组的目标文档提供所有四个心室更新正常值,包括三维回声心电图和心电图变形,并视可能基于从多数据库编译的大得多正常题此外,本文件还试图消除先前发布指南之间存在的若干小差错

抽象性 :Preamble.E4APDIX1.E121APDENIX2.E122APDENIX3.E124参考.e124